US healthcare giant Johnson & Johnson (NYSE: JNJ) announced its fourth-quarter and annual financial results for 2023 on Tuesday.
The firm reported fourth-quarter reported sales growth of 7.3% to $21.4 billion, which was 2% higher than the consensus estimate of analysts, according to Leerink Partners.
The fourth-quarter adjusted earnings per share figure of $2.29 - compared to last year's $2.05 - was essentially in line with the consensus estimate of $2.28, and would have been greater had it not been for operating income being 7% below the expected amount.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze